Commons Capital LLC Cuts Johnson & Johnson (NYSE:JNJ) Stake

VaselineSeptember 6, 2024

0 4 minutes read

Commons Capital LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 8.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,049 shares of the company’s stock after selling 194 shares during the quarter. Commons Capital LLC’s holdings in Johnson & Johnson were worth $299,000 at the end of the most recent quarter.

Several other hedge funds have recently made changes to their positions in JNJ. Inçalta Capital LLC purchased a new stake in Johnson & Johnson in the second quarter valued at approximately $27,000. Christopher J. Hasenberg Inc bought a new position in shares of Johnson & Johnson in the 1st quarter worth about $31,000. MFA Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson in the second quarter valued at about $43,000. Vermillion & White Wealth Management Group LLC purchased a new stake in Johnson & Johnson in the fourth quarter valued at $44,000. Finally, Grayhawk Investment Strategies Inc. boosted its holdings in Johnson & Johnson by 528.6% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after purchasing an additional 259 shares during the last quarter. 69.55% of the shares are held by hedge funds and other institutional investors.

Johnson & Johnson stock performance

Shares of JNJ stock opened at $164.99 on Friday. The firm has a market cap of $397.08 billion, a PE ratio of 10.29, a P/E/G ratio of 2.73 and a beta of 0.52. The company has a 50-day moving average price of $157.21 and a 200-day moving average price of $153.78. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The company has a quick ratio of 0.85, a current ratio of 1.07, and a debt-to-equity ratio of 0.44.

Want more great investment ideas?

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the prior year, the business earned $2.80 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson announces dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be given a $1.24 dividend. The ex-dividend date is Tuesday, August 27. This represents an annualized dividend of $4.96 and a yield of 3.01%. Johnson & Johnson’s payout ratio is 30.92%.

Insider buying and selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. Corporate insiders own 0.16% of the company’s shares.

Analyst upgrades and downgrades

JNJ has been the subject of a number of research reports. TD Cowen decreased their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Friday, August 16th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a report on Thursday, July 18th. Sanford C. Bernstein boosted their price target on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Tuesday. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Moderate Buy” and an average target price of $173.21, according to MarketBeat.

Read our latest review of JNJ

Johnson & Johnson profile

(Free report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.